92 related articles for article (PubMed ID: 18054775)
1. Inhibition of squalene synthase upregulates PCSK9 expression in rat liver.
Bedi M; Niesen M; Lopez D
Arch Biochem Biophys; 2008 Feb; 470(2):116-9. PubMed ID: 18054775
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of cholesterol biosynthesis increase hepatic low-density lipoprotein receptor protein degradation.
Ness GC; Zhao Z; Lopez D
Arch Biochem Biophys; 1996 Jan; 325(2):242-8. PubMed ID: 8561503
[TBL] [Abstract][Full Text] [Related]
3. Effect of squalene synthase inhibition on the expression of hepatic cholesterol biosynthetic enzymes, LDL receptor, and cholesterol 7 alpha hydroxylase.
Ness GC; Zhao Z; Keller RK
Arch Biochem Biophys; 1994 Jun; 311(2):277-85. PubMed ID: 7911291
[TBL] [Abstract][Full Text] [Related]
4. Compensatory responses to inhibition of hepatic squalene synthase.
Lopez D; Chambers CM; Keller RK; Ness GC
Arch Biochem Biophys; 1998 Mar; 351(2):159-66. PubMed ID: 9514656
[TBL] [Abstract][Full Text] [Related]
5. Zaragozic acids: a family of fungal metabolites that are picomolar competitive inhibitors of squalene synthase.
Bergstrom JD; Kurtz MM; Rew DJ; Amend AM; Karkas JD; Bostedor RG; Bansal VS; Dufresne C; VanMiddlesworth FL; Hensens OD
Proc Natl Acad Sci U S A; 1993 Jan; 90(1):80-4. PubMed ID: 8419946
[TBL] [Abstract][Full Text] [Related]
6. Farnesol is not the nonsterol regulator mediating degradation of HMG-CoA reductase in rat liver.
Keller RK; Zhao Z; Chambers C; Ness GC
Arch Biochem Biophys; 1996 Apr; 328(2):324-30. PubMed ID: 8645011
[TBL] [Abstract][Full Text] [Related]
7. Squalestatin 1, a potent inhibitor of squalene synthase, which lowers serum cholesterol in vivo.
Baxter A; Fitzgerald BJ; Hutson JL; McCarthy AD; Motteram JM; Ross BC; Sapra M; Snowden MA; Watson NS; Williams RJ
J Biol Chem; 1992 Jun; 267(17):11705-8. PubMed ID: 1601846
[TBL] [Abstract][Full Text] [Related]
8. Regulation of rat hepatic cytochrome P450 expression by sterol biosynthesis inhibition: inhibitors of squalene synthase are potent inducers of CYP2B expression in primary cultured rat hepatocytes and rat liver.
Kocarek TA; Kraniak JM; Reddy AB
Mol Pharmacol; 1998 Sep; 54(3):474-84. PubMed ID: 9730906
[TBL] [Abstract][Full Text] [Related]
9. Massive production of farnesol-derived dicarboxylic acids in mice treated with the squalene synthase inhibitor zaragozic acid A.
Vaidya S; Bostedor R; Kurtz MM; Bergstrom JD; Bansal VS
Arch Biochem Biophys; 1998 Jul; 355(1):84-92. PubMed ID: 9647670
[TBL] [Abstract][Full Text] [Related]
10. Squalene synthase inhibition alters metabolism of nonsterols in rat liver.
Keller RK
Biochim Biophys Acta; 1996 Oct; 1303(3):169-79. PubMed ID: 8908150
[TBL] [Abstract][Full Text] [Related]
11. Lipid-lowering properties of TAK-475, a squalene synthase inhibitor, in vivo and in vitro.
Nishimoto T; Amano Y; Tozawa R; Ishikawa E; Imura Y; Yukimasa H; Sugiyama Y
Br J Pharmacol; 2003 Jul; 139(5):911-8. PubMed ID: 12839864
[TBL] [Abstract][Full Text] [Related]
12. Diabetes alters LDL receptor and PCSK9 expression in rat liver.
Niesen M; Bedi M; Lopez D
Arch Biochem Biophys; 2008 Feb; 470(2):111-5. PubMed ID: 18054320
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of squalene synthase but not squalene cyclase prevents mevalonate-mediated suppression of 3-hydroxy-3-methylglutaryl coenzyme A reductase synthesis at a posttranscriptional level.
Peffley DM; Gayen AK
Arch Biochem Biophys; 1997 Jan; 337(2):251-60. PubMed ID: 9016820
[TBL] [Abstract][Full Text] [Related]
14. Discovery, biosynthesis, and mechanism of action of the zaragozic acids: potent inhibitors of squalene synthase.
Bergstrom JD; Dufresne C; Bills GF; Nallin-Omstead M; Byrne K
Annu Rev Microbiol; 1995; 49():607-39. PubMed ID: 8561474
[TBL] [Abstract][Full Text] [Related]
15. Regulation of fatty acid synthase expression by cholesterol in human cultured cells.
Kawabe Y; Sato R; Matsumoto A; Honda M; Wada Y; Yazaki Y; Endo A; Takano T; Itakura H; Kodama T
Biochem Biophys Res Commun; 1996 Feb; 219(2):515-20. PubMed ID: 8605019
[TBL] [Abstract][Full Text] [Related]
16. Zaragozic acids D and D2: potent inhibitors of squalene synthase and of Ras farnesyl-protein transferase.
Dufresne C; Wilson KE; Singh SB; Zink DL; Bergstrom JD; Rew D; Polishook JD; Meinz M; Huang L; Silverman KC
J Nat Prod; 1993 Nov; 56(11):1923-9. PubMed ID: 8289063
[TBL] [Abstract][Full Text] [Related]
17. The squalestatins: decarboxy and 4-deoxy analogues as potent squalene synthase inhibitors.
Chan C; Andreotti D; Cox B; Dymock BW; Hutson JL; Keeling SE; McCarthy AD; Procopiou PA; Ross BC; Sareen M; Scicinski JJ; Sharratt PJ; Snowden MA; Watson NS
J Med Chem; 1996 Jan; 39(1):207-16. PubMed ID: 8568810
[TBL] [Abstract][Full Text] [Related]
18. Total synthesis of the squalene synthase inhibitor zaragozic acid C by a carbonyl ylide cycloaddition strategy.
Nakamura S; Hirata Y; Kurosaki T; Anada M; Kataoka O; Kitagaki S; Hashimoto S
Angew Chem Int Ed Engl; 2003 Nov; 42(43):5351-5. PubMed ID: 14613174
[No Abstract] [Full Text] [Related]
19. Comparative study of the inhibition of rat and tobacco squalene synthase by squalestatins.
Fulton DC; Tait M; Threlfall DR
Phytochemistry; 1995 Mar; 38(5):1137-41. PubMed ID: 7766395
[TBL] [Abstract][Full Text] [Related]
20. Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo.
Schmidt RJ; Beyer TP; Bensch WR; Qian YW; Lin A; Kowala M; Alborn WE; Konrad RJ; Cao G
Biochem Biophys Res Commun; 2008 Jun; 370(4):634-40. PubMed ID: 18406350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
